New Models for Testing Parkinson's Disease Immune–based Drugs
Using powerful, newly developed cell culture and mouse models of sporadic Parkinson's disease (PD), a team of researchers from the Perelman School of Medicine at the University of Pennsylvania has demonstrated that immunotherapy with specifically targeted antibodies may block the development and spread of PD pathology in the brain. By intercepting the distorted and misfolded alpha-sinuclein (a-syn) proteins that enter and propogate in neurons, creating aggregates, the researchers prevented the development of pathology and also reversed some of the effects of already-existing disease. The a-syn clumps, called Lewy bodies, eventually kill affected neurons, which leads to clinical PD.
Penn Medicine News Release
Full Cell Reports
UDALL in the News
Participate in Study
© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team